Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.55 |
| ▸ | LONP1 | P36776 | 4/20 | 0.55 |
| ▸ | PSMB11 | A5LHX3 | 3/20 | 0.55 |
| ▸ | PSMA7 | O14818 | 3/20 | 0.55 |
| ▸ | PSMB1 | P20618 | 3/20 | 0.55 |
| ▸ | PSMA1 | P25786 | 3/20 | 0.55 |
| ▸ | PSMA2 | P25787 | 3/20 | 0.55 |
| ▸ | PSMA3 | P25788 | 3/20 | 0.55 |
| ▸ | PSMA4 | P25789 | 3/20 | 0.55 |
| ▸ | PSMB8 | P28062 | 3/20 | 0.55 |
| ▸ | PSMB9 | P28065 | 3/20 | 0.55 |
| ▸ | PSMA5 | P28066 | 3/20 | 0.55 |
| ▸ | PSMB4 | P28070 | 3/20 | 0.55 |
| ▸ | PSMB6 | P28072 | 3/20 | 0.55 |
| ▸ | PSMB10 | P40306 | 3/20 | 0.55 |
| ▸ | PSMB3 | P49720 | 3/20 | 0.55 |
| ▸ | PSMB2 | P49721 | 3/20 | 0.55 |
| ▸ | PSMA6 | P60900 | 3/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420556 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2HTTPSMB5LONP1PSMB11 | |
| Hydrochloric Acid SCHEMBL27788898 | 0.98 | SMN1; SMN2 (0.55) | SMN1; SMN2HTTPSMB5LONP1PSMB11 | |
| SCHEMBL28159463 | 0.86 | KDM4E (0.51) | SMN1; SMN2HTTPSMB5LONP1PSMB11 | |
| SCHEMBL9607087 | 0.85 | LONP1 (0.55) | SMN1; SMN2HTTPSMB5LONP1PSMB11 | |
| SCHEMBL27890664 | 0.84 | LONP1 (0.58) | SMN1; SMN2HTTPSMB5LONP1PSMB11 | |
| SCHEMBL8293294 | 0.84 | KDM4E (0.58) | SMN1; SMN2HTTPSMB5LONP1PSMB11 | |
| SCHEMBL13127955 | 0.84 | LONP1 (0.58) | SMN1; SMN2HTTPSMB5LONP1PSMB11 | |
| SCHEMBL9607089 | 0.84 | LONP1 (0.58) | SMN1; SMN2HTTPSMB5LONP1PSMB11 | |
| SCHEMBL24882564 | 0.83 | SMN1; SMN2 (0.51) | SMN1; SMN2HTTPSMB5LONP1PSMB11 | |
| SCHEMBL29420559 | 0.83 | SMN1; SMN2 (0.54) | SMN1; SMN2HTTPSMB5LONP1PSMB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| EP-4249480-A1 | DIPHENYLPYRAZOLE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Northwest A&F University (CN) | 2023-09-27 | — | — | EP | disclosed |
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-06-03 | — | — | US | disclosed |
| US-11008358-B2 | Synthesis of desosamines | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200347087-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2020-11-05 | — | — | US | disclosed |
| US-10695328-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190314346-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-10-17 | — | — | US | disclosed |
| US-10022354-B2 | Pyrrolidine amide compounds as histone demethylase inhibitors | GENENTECH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10022354-B2 | Pyrrolidine amide compounds as histone demethylase inhibitors | GENENTECH, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180111956-A1 | SYNTHESIS OF DESOSAMINES | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170312252-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-9663466-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-05-30 | — | — | US | disclosed |
| US-8962244-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2015-02-24 | — | — | US | disclosed |
| US-20130217685-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | UNIVERSITY OF MASSACHUSETTS (US) | 2013-08-22 | — | — | US | disclosed |
| US-8377639-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2013-02-19 | — | — | US | disclosed |
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. | 2012-10-11 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-17 | — | — | US | disclosed |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2011-02-03 | — | — | US | disclosed |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217685-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | SMN1; SMN2 2721/4885HTT 2323/4885PSMB5 2014/4885 |
| US-11008358-B2 | Synthesis of desosamines | NANS, GALE, FUT6 | SMN1; SMN2 4172/4885HTT 2979/4885PSMB5 1357/4885 |
| US-20190314346-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | SMN1; SMN2 4109/4885HTT 2561/4885PSMB5 2922/4885 |
| US-20120258963-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | SMN1; SMN2 3387/4885HTT 2948/4885PSMB5 1427/4885 |
| US-20090253705-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | SMN1; SMN2 3387/4885HTT 2948/4885PSMB5 1427/4885 |
| US-20170312252-A1 | PYRROLIDINE AMIDE COMPOUNDS AS HISTONE DEMETHYLASE INHIBITORS | KDM5A, KDM5C, KDM5B | SMN1; SMN2 2278/4885HTT 686/4885PSMB5 535/4885 |
| US-20180111956-A1 | SYNTHESIS OF DESOSAMINES | NANS, GALE, FUT6 | SMN1; SMN2 4172/4885HTT 2979/4885PSMB5 1357/4885 |
| US-20110028461-A1 | HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS | ADRB3, ADRB1, ADRB2 | SMN1; SMN2 3396/4885HTT 3163/4885PSMB5 1400/4885 |
| US-20200347087-A1 | SYNTHESIS OF DESOSAMINES | NANS, GALE, FUT6 | SMN1; SMN2 4172/4885HTT 2979/4885PSMB5 1357/4885 |
| US-10022354-B2 | Pyrrolidine amide compounds as histone demethylase inhibitors | KDM5A, KDM5C, KDM1B | SMN1; SMN2 2301/4885HTT 768/4885PSMB5 577/4885 |
| US-20210161869-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | SMN1; SMN2 4109/4885HTT 2561/4885PSMB5 2922/4885 |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | SMN1; SMN2 2721/4885HTT 2323/4885PSMB5 2014/4885 |
| US-10695328-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | SMN1; SMN2 4109/4885HTT 2561/4885PSMB5 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.